A Novel Eye Wash Solution for DED Treatment
2026年11月11日 更新者:Jiaxu Hong、Eye & ENT Hospital of Fudan University
A single-center, randomized, participant-masked, placebo-controlled, parallel-group clinical trial designed to evaluate the effectiveness and safety of a novel eye wash solution for the treatment of dry eye disease
研究概览
研究类型
介入性
注册 (估计的)
30
阶段
- 第一阶段早期
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Jiaxu Hong, Department chief
- 电话号码:021-64377134
- 邮箱:Jiaxu.hong@fdeent.org
学习地点
-
-
-
Shanghai、中国
- Fudan Eye, Ear, Nose and Throat Hospital
-
接触:
- Jiaxu Hong
- 电话号码:021-64377134
- 邮箱:Jiaxu.hong@fdeent.org
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Age of at least 18 years at the time of signing the informed consent. Provision of written informed consent.
- Tear film break-up time (TBUT) < 10 seconds at both Visit 0 and Visit 1. Ocular Surface Disease Index (OSDI) score ≥ 13 at both Visit 0 and Visit 1. Meibomian gland dysfunction (MGD) score ≥ 3 at Visit 0 or Visit 1.
- Presence of cloudy meibum; or 3 or 4 out of 5 meibomian glands expressible upon eyelid compression; or meibomian gland dropout count ≥ 5 at both Visit 0 and Visit 1.
- Meibomian gland dysfunction scoring: MGD is scored based on the secretion of the central 5 meibomian glands of the lower eyelid. Each gland is scored from 0 to 3 (0 = normal; 1 = thick, yellow-white particles; 2 = paste-like secretion; 3 = no secretion or obstruction), with a total score of 0-15 [12].
- Total corneal fluorescein staining score of 1 < X < 10 (sum of inferior, superior, central, nasal, and temporal regions) according to the National Eye Institute (NEI) grading system at both Visit 0 and Visit 1.
- At both Visit 0 and Visit 1, at least one eye (the same eye) must meet all criteria of items 3, 4, 5, and 6 above.
- Ability and willingness to follow instructions, including participation in all study assessments and visits.
Exclusion Criteria:
- Any clinically significant abnormal findings on slit-lamp examination of the ocular surface at both Visit 0 and Visit 1, or any findings that, in the investigator's judgment, may affect study parameters, which may include ocular trauma, history of ocular trauma, or anterior membrane disease.
- History of Stevens-Johnson syndrome; use of any oral medications known to cause dry eyes (e.g., antihistamines, antidepressants, etc.) within 1 month prior to Visit 0, or expected instability during the study period.
- Active ocular infection; use of any topical antibiotics or topical steroids within 14 days prior to the visit, or potential need for such treatment during the study. Any other eyelid margin treatments, such as meibomian gland expression, systemic antibiotics (e.g., tetracyclines), and oral supplements for eye diseases (e.g., lutein) must remain stable for 14 days prior to the visit and throughout the study period.
- Receipt of LipiFlow, intense pulsed light (IPL), or any other procedures affecting the meibomian glands within 1 month prior to Visit 1.
- Abnormal eyelid structure preventing complete eyelid closure, including entropion, ectropion, or floppy eyelid syndrome, which may cause partial conjunctival exposure or affect eyelid blinking function.
- Placement or removal of a permanent punctal plug within 3 months prior to Visit 1 (or 6 months for dissolvable plugs); or expected placement or removal of a punctal plug at this visit, or expected dissolution of the punctal plug during the study.
- Dry eye caused by scarring, radiation injury, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (commonly seen in vitamin A deficiency).
- Ocular or periocular malignancy.
- Corneal epithelial defect; significant confluent staining or filaments in any part of the cornea.
- History of herpes keratitis.
- Significant ocular allergy symptoms, or expected persistent allergic conditions during the study.
- Diagnosis of active ocular or systemic infection (bacterial, viral, or fungal) accompanied by fever requiring antibiotic treatment.
- Use of contact lenses within 14 days prior to Visit 0, or expected use of contact lenses during the study.
- Any intraocular, corneal, or ocular laser surgery within the past 6 months, or any planned ocular and/or eyelid surgery during the study.
- Employees of the clinical trial site directly involved in the management, administration, or support of this trial, or immediate family members of the same trial site.
- Women who are pregnant, breastfeeding, or planning to become pregnant.
- For women of childbearing potential, refusal to undergo urine pregnancy testing at Visit 0, Visit 1, Visit 2, and Visit 3 (or early termination visit) will be considered a refusal of testing. Non-childbearing potential is defined as permanently sterilized (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (no menstruation for 12 consecutive months).
- Women of childbearing potential not using effective contraception. Acceptable contraceptive methods include: hormonal oral contraceptives, implantable contraceptive devices, injectable contraceptives, or transdermal contraceptives; mechanical spermicides combined with barrier devices such as a diaphragm or condom; intrauterine devices; or surgical sterilization of the partner. For women who are not sexually active, abstinence may be considered an effective contraceptive method; however, if the subject becomes sexually active during the trial, she must agree to use appropriate contraception as defined above for the remainder of the trial.
- Presence of an uncontrolled systemic disease, in the investigator's judgment. Known allergic reaction to the investigational drug or its components. Significant ocular or periocular rosacea that, in the investigator's judgment, interferes with the trial (e.g., clinically significant facial induration).
- Pterygium in either eye.
- Current participation in an investigational drug or device study, or use of an investigational drug or device within 60 days after Visit 1.
- Non-use of any lipid-based artificial tears (e.g., perfluorohexyloctane ophthalmic solution, etc.), no application of warm compresses, and no use of any eye drops and/or "TrueTear™" device (intranasal tear neurostimulator) within 3 days prior to this visit.
- Presence of systemic immune diseases, such as systemic lupuserythematosus, rheumatoid arthritis, ankylosing spondylitis, Sjögren's syndrome, etc.
- Best-corrected visual acuity ≥ 4.3 in both eyes at Visit 0 and Visit 1 (5-point recording method on the international standard logarithmic visual acuity chart at 5 meters).
- Any condition or circumstance (including language barriers) that, in the investigator's judgment, may place the subject at significant risk, may interfere with study results, or may significantly hinder the subject's participation in the study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂组
|
Saline (NaCl 0.9 %), one drop per eye, 3 times daily (TID) for 28 days. |
|
实验性的:Eye Wash Solution Arm
|
0.2% DHA eye wash solution, one drop per eye, 3 times daily (TID) for 28 days. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Corneal Fluorescein Staining (CFS) Score
大体时间:Baseline (Visit 1) to Day 28 (Visit 3)
|
Change from baseline in corneal fluorescein staining score (total score 0-15) in the study eye. |
Baseline (Visit 1) to Day 28 (Visit 3)
|
|
Change in Ocular Surface Disease Index (OSDI) Score
大体时间:Baseline (Visit 1) to Day 28 (Visit 3)
|
Change from baseline in OSDI score (ranging from 0 to 100) to assess dry eye symptoms. |
Baseline (Visit 1) to Day 28 (Visit 3)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年11月1日
初级完成 (估计的)
2026年11月1日
研究完成 (估计的)
2027年11月1日
研究注册日期
首次提交
2026年11月11日
首先提交符合 QC 标准的
2026年11月11日
首次发布 (实际的)
2026年11月16日
研究记录更新
最后更新发布 (实际的)
2026年11月16日
上次提交的符合 QC 标准的更新
2026年11月11日
最后验证
2026年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.